Rafarma Pharmaceuticals, Inc.
RAFA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.4% | -84.2% | -16.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 7.4% | 5.9% | 35.5% | 35.2% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 3.8% | 5.2% | 10% | 19% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 2.9% | 2.7% | 7.7% | 15% |
| EPS Diluted | 0.003 | 0.003 | 0.057 | 0.13 |
| % Growth | -3.2% | -94.5% | -56.5% | – |
| Operating Cash Flow | $0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |